AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04735549 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual Analogue Scale (VAS)
Description: Visual Analogue Scale will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
Study NCT04958109 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test
Description: Administration of a 75 gm oral glucose tolerance test
Study NCT04958109 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Oral Glucose Tolerance Test
Description: Administration of a 75 gm oral glucose tolerance test
Study NCT04958109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin
Description: Intravenous administration of kisspeptin 112-121 x 16 hours
Study NCT04958109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration of Placebo 16 hours
Study NCT06426550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Description: An experienced periodontist will access clinical periodontal parameters, including plaque index, bleeding on probing, pocket probing depth, gingival recession, clinical attachment level using a periodontal probe, at six sites per tooth at all teeth, excluding third molars.~Conventional periodontal treatment, scaling and root planning, will be performed with ultrasound (Dabi Atlante, Rio de Janeiro, RJ, Brazil) complemented with Gracey curettes (Golgran, São Caetano do Sul, SP, Brazil) on each patient under local anesthesia. The maintenance therapy will include professional plaque control and scaling and root planning in recurrent periodontal pockets, every 30 days, until 3 months, when the periodontal parameters will be reassessed.
Study NCT06426550 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Periodontal treatment
Description: An experienced periodontist will access clinical periodontal parameters, including plaque index, bleeding on probing, pocket probing depth, gingival recession, clinical attachment level using a periodontal probe, at six sites per tooth at all teeth, excluding third molars.~Conventional periodontal treatment, scaling and root planning, will be performed with ultrasound (Dabi Atlante, Rio de Janeiro, RJ, Brazil) complemented with Gracey curettes (Golgran, São Caetano do Sul, SP, Brazil) on each patient under local anesthesia. The maintenance therapy will include professional plaque control and scaling and root planning in recurrent periodontal pockets, every 30 days, until 3 months, when the periodontal parameters will be reassessed.
Study NCT05099042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recommendations and re-orientation towards appropriate physical, mental, and social health ressources
Description: Resources recommendations and interventions curated to the needs of the EP such as refering them to a social activity for socially isolated EP.
Study NCT04728529 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: USSM protocol
Description: In the initial step, all subjects will receive emergency management: oxygen support, vascular access, and fluid therapy. Doppler ultrasonography by Ultrasound Cardiac Output Monitoring (USCOM) is also performed to record initial stroke volume (SV), cardiac index (CI), and systemic vascular resistance (SVR). The initial fluid resuscitation is 20 mL/kg body weight, then the response measured by clinical and USCOM examination. If any improvement of clinical sign and normal SVI, CI, SVR, intervention will be stopped. In contrary, if shock persist, subsequent fluid resuscitation and/or vasoactive therapy will be administered, guided by USCOM.~The therapeutic goal of USCOM: SVI 30-60 mL/m2, CI 3.3-6.0 L/minute/m2, and SVRI 800-1600 d.s/cm5/m2
Study NCT04728529 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACCM protocol
Description: In the initial step, all subjects will receive emergency management: oxygen support, vascular access, and fluid therapy. Doppler ultrasonography by Ultrasound Cardiac Output Monitoring (USCOM) is also performed to record initial stroke volume (SV), cardiac index (CI), and systemic vascular resistance (SVR). The initial fluid resuscitation is 20 mL/kg body weight, then the response measured by clinical. If any improvement of clinical sign, intervention will be stopped. In contrary, if shock persist, subsequent fluid resuscitation and/or vasoactive therapy will be administered, guided by clinical parameter.
Study NCT06111456 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Online self-administered questionnaire to quantitatively mesure parental knowledge and expectations on current and expanded newborn screeing and parental acceptability of expanded newborn screening using genetic.
Study NCT06111456 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Semi-structured interview to explore parental representations on the extension of newborn screening and - if concerned - to retrace the screening/diagnosis/care management pathway
Study NCT06496633 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous Intramyocardial Septal Radiofrequency Ablation
Description: PIMSRA procedure represents a significant breakthrough in the treatment of HOCM patients, as it uses a unique transmyocardial approach to directly and precisely insert a radiofrequency electrode needle into the hypertrophied IVS for targeted ablation
Study NCT04730050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TT-01025-CL
Description: Oral tablet
Study NCT04730050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-01025-CL
Description: Oral tablet
Study NCT04984850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral chemotherapy information and support
Description: Multimodal intervention : (1) handouts and videos presenting information and supportive resources for common oral chemotherapy related issues, (2) phone call(s) from a nurse in oncology, and (3) e-reminders to take medication. The intervention will be available to experimental group participants on mobile platform.
Study NCT05365893 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Paricalcitol, Hydroxychloroquine, Losartan
Description: Paricalcitol 25 mcg IV administered M-W-F Hydroxychloroquine 600 mg PO BID Losartan 50 mg PO daily
Study NCT05365893 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant therapy and surgery only (Control)
Description: Control arm These patients will proceed to surgery at completion of neoadjuvant therapy.
Study NCT05770479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivationally-Enhanced Compensatory Cognitive Training (ME-CCT) Booster Modules
Description: ME-CCT is a traditionally a manualized group-based behavioral intervention (8 weeks, 2 hours per week) designed to improve cognitive and everyday functioning in patients with MCI. Our booster modules will be shortened and distilled from ME-CCT using the IM Adapt protocol (and thus will not be new information but rather 'reminder' content) for a personalized four-session sequence of booster training targeted toward specific everyday functional needs of individual participants.
Study NCT05770479 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment As Usual
Description: Treatment for MCI is generally managed by Primary Care or Neurology. Participants will continue to receive their usual care with their current providers. With no effective pharmacological treatment known for persons with MCI, providers tend to focus on encouraging a healthy lifestyle, prevention and management of modifiable risk factors for cognitive impairment, and treatment of behavioral and psychiatric symptoms.
Study NCT06347302 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood sampling
Description: Two tubes will be taken, the first tube (Tube 1) for specialised lipid analysis. The second tube (Tube 2) for routine biochemical analysis
Study NCT06347302 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Two tubes will be taken, the first tube (Tube 1) for specialised lipid analysis. The second tube (Tube 2) for routine biochemical analysis
Study NCT06347302 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: vitreous sampling
Description: Intra-operative vitreous sampling: systematic collection of the vitreous humour during vitrectomy for vitreoretinal surgery such as retinal detachment, epiretinal membranes and macular holes.
Study NCT06347302 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: vitreous sampling
Description: Intra-operative vitreous sampling: systematic collection of the vitreous humour during vitrectomy for vitreoretinal surgery such as retinal detachment, epiretinal membranes and macular holes.
Study NCT06347302 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sub-retinal fluid sampling
Description: Sub-retinal fluid sampling consists of collecting the sub-retinal fluid that is systematically aspirated during retinal detachment surgery in order to dry the detached retina and allow retinopexy to be performed.
Study NCT06347302 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Retinal tissue sampling
Description: cutting and aspiration of the retina using the vitreotome opposite the tear to allow access to the sub-retinal fluid.
Study NCT06580236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B11-FC
Description: Infusion
Study NCT06580236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B11-FC
Description: Infusion
Study NCT06580236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum neurotoxin type A
Description: Infusion
Study NCT06580236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Botulinum neurotoxin type A
Description: Infusion
Study NCT06580236 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion
Study NCT05460416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: 160mg once a day
Study NCT05853861 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JASPER
Description: JASPER is an evidence based early intervention that focuses on the core social communication and engagement skills of young children that are important to improvements in communication and language.
Study NCT05853861 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Babble Bootcamp
Description: Babble Bootcamp is a new intervention focusing on the speech-motor system and aims to improve babbling and early word use in infants known to be at risk for language delay.
Study NCT06510543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Goal-directed EN therapy
Description: The participants will be administered a supervised goal-directed nutritional therapy. The enteral nutrition (EN) regimens include homemade meals with or without ORAL IMPACT® according to the daily goal.
Study NCT06510543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional EN therapy
Description: The participants will be administered the conventional nutritional therapy according to the Chinese expert consensus on perioperative nutritional support in enhanced recovery after surgery (2019 edition).
Study NCT06129916 — intervention group
Intervention type: DRUG
Intervention: long-acting depot buprenorphine (LADB)
Description: The intervention will measure patient-centered outcomes in people initiating LADB among a cohort of opioid-dependent PWID across sites in the seven project LMIC. Study participants will be enrolled from selected clinics that deliver routine opioid agonist maintenance treatment to PWID. The intervention will 1) Compare characteristics at baseline of those service clients who do and do not initiate LADB in relation to demographic characteristics, history of drug use, and outcomes; 2) Measure side effects and adverse events among those initiating LADB; and 3) Where appropriate, assess changes in outcomes between time of LADB initiation and 48 week follow-up, including HCV and HIV testing and treatment, quality of life, employment opportunities, and service preferences.
Study NCT04818840 — intervention group
Intervention type: DEVICE
Intervention: Resurfaced Patella
Description: JOURNEY II CR Total Knee System was used for Total Knee replacement
Study NCT04818840 — intervention group
Intervention type: PROCEDURE
Intervention: Un-resurfaced Patella
Description: JOURNEY II CR Total Knee System was used for Total Knee replacement
Study NCT05904834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flexibility training
Description: Each session consisted of three or four exercises, of which three were static stretches and if there was a fourth, it was dynamic. The duration of each exercise was 20 seconds with 15 seconds rest between sets and 30 seconds rest between exercises.
Study NCT04047836 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low Nicotine E-Liquid
Description: Participants will vape e-liquid with nicotine concentration of 3 mg/ml.
Study NCT04047836 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medium or High Nicotine E-Liquid
Description: Participants will vape either e-liquid with nicotine concentration of 18 mg/ml or a JUUL device with JUUL pod of 59 mg/ml nicotine e-liquid.
Study NCT05355584 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy application
Description: The temperature sense test was applied on the dominant side shoulder of the participants against the risk of sensory loss or decreased sensation. In order to test cold intolerance, a cold pack was placed on the forearm of the individuals. After waiting 2-3 minutes, the region was evaluated. Individuals meeting the inclusion criteria were assigned to the groups according to the randomization list created by the computer. Then, the participants' shoulder isometric muscle strength, shoulder flexibility, shoulder endurance and shoulder balance was evaluated. Except for shoulder endurance, all measurements were repeated three times, with a 30-second rest period between each repetition. A 2-3-minute rest period was given after each test. Then, the cold pack was wrapped in a thin and wet cloth on the shoulders of the participants. The treated area was checked every 5 minutes and the participants were asked to say when they felt any unusual symptoms.
Study NCT04782297 — intervention group
Intervention type: DEVICE
Intervention: Long term hemodialysis catheter
Description: There will be no interventions in this study. Strictly observational.
Study NCT06401473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ipsilateral Scratch Task
Description: Patients scratch the skin within the relevant cervical dermatome, ipsilateral to the injection site
Study NCT06401473 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Motor Distraction Task
Description: Patients scratch the skin of the shoulder/neck contralateral to the injection site
Study NCT06575244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based sailing
Description: A nature-based intervention, the Resilience AND Well-being Building through Oceanic Nautical Empowerment (RAWBONE) sailing program is validated by an expert panel including professionals from various fields, such as a registered nurse, educators specializing in NBIs, occupational therapists, physiotherapists, clinical psychologists, speech therapists, academics specializing in children's well-being, pediatricians, and qualified sailing instructors, delivered in a group of 6 participants, incorporating experiential learning and positive reinforcement, with the aid of materials including dinghies with Universal design, safety boats, buoys, buoyancy aids, supplementing with a waterproof sailing booklet and social skills booklet. The intervention is developed and facilitated by a registered nurse (principal investigator).
Study NCT06575244 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: A self-developed social skill booklet
Study NCT06575244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: A self-developed social skill booklet
Study NCT06520592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: With AR guided CPAP therapy
Description: Participants will received AR training course to utilize the AR guided CPAP therapy
Study NCT05184504 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
Study NCT06574841 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Flow Restriction training
Description: BFR training done 3 sessions per week, each session includes low intensity of 20% to 30% of 1RM, 3 sets of 15 to 30 reps with a 30sec resting period done for 6 weeks.Moreover, nerve and tendon-gliding exercises consists of 10 reps with a 5-second hold, 3-5 times done daily for 5 weeks.
Study NCT06574841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction training
Description: BFR training done 3 sessions per week, each session includes low intensity of 20% to 30% of 1RM, 3 sets of 15 to 30 reps with a 30sec resting period done for 6 weeks.Moreover, nerve and tendon-gliding exercises consists of 10 reps with a 5-second hold, 3-5 times done daily for 5 weeks.
Study NCT06353685 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Continuous, hyperfractionated, accelerated radiotherapy(CHART)
Description: high-risk CTV area (CTV1), 45Gy in total, fraction dose of 1.5Gy, twice a day, bioequivalent dose (BED) of 51.75Gy; Low-risk CTV area(CTV2), 39Gy in total , fraction dose of 1.3Gy, twice a day, BED of 44.07Gy; A total of 30 radiotherapy fraction were performed 10 times a week for 3 weeks.
Study NCT05566470 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of Central Neuromuscular Dysfunction, Shoulder Physical Functionality and Psychological Factors
Description: Each of the 2 groups will be evaluated in terms of functional level and psychological factors; American Shoulder and Elbow Surgeons evaluation form (ASES), Connor-Davidson Psychological Resilience Scale (CDPRS) and the Depression, Anxiety, Stress-21 Scale (DASS-21) will be used to evaluate these factors. Furthermore, the corticospinal excitability of the deltoid muscle will be assessed with Transcranial Magnetic Stimulation (TMS). Both deltoid muscles of the patient will be evaluated by saving motor evoked potentials signals that respond to TMS, and motor excitability will be compared between the affected arm and the unaffected arm. In addition, the control group will also be assessed in terms of functional level and psychological factors with TMS, ASES, DASS-21 and CPDRS.
Study NCT05577013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesiotaping
Description: It will be applied by kinesiotape certified physiotherapist on tendons in the direction of extensor muscle to facilitate range of motion by stretching 50%. At first it will be applied on extensor pollicis longus and extensor pollicis brevis muscles of hand, extensor digitorum and extensor indicis of last 4 fingers of hand. Triceps brachii in arm and Supraspinatus and Infraspinatus muscles to stabilize the gelnohumeral joint
Study NCT05577013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: motor relearning program
Description: Stacking up blocks Stacking up polystyrene cups Folding piece of cloth Using cutlery Pouring water into glass Closing/opening lid of bottles turning the pages of books or newspaper writing on paper Squeezing of ball Coloring in different shapes
Study NCT06291038 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: • Experimental group: treatment with glutamine at a dose of 5g 3 times a day for 8 weeks
Description: treatment with glutamine at a dose of 5g 3 times a day for 8 weeks
Study NCT06291038 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: • Control group: treatment with a protein powder (Protifar) (Placébo) 5g 3 times a day for 8 weeks.
Description: treatment with a protein powder (Protifar) (Placébo) 5g 3 times a day for 8 weeks.
Study NCT06276868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalcilib+letrozole+HP treatment group
Description: All participants received 150mg of darcilib once a day. Take it continuously for 21 days, then stop taking it for 7 days, with a treatment cycle of 28 days.~Letrozole 2.5mg once daily (premenopausal patients treated with OFS); Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and Patuzumab (840mg first dose, 420mg/kg sequential) were administered intravenously every 3 weeks, or fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL), both administered every 3 weeks.
Study NCT06246604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound screening for lower limbs DVT
Description: Using a linear ultrasound probe (7.5-12 MHz) a compression ultrasound of the lower limbs is performed, from the hip to the ankle. The exam is completed by the use of Doppler.
Study NCT06246604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care
Description: Ultrasound examination of lower limbs is performed according to clinical risk of DVT